{"ATC Code":"N05BA12","Abbreviation":"Xanax","Aliases":["Niravam","Tranquinal","Alplax","Constan","Frontal","Solanax","Xanor","Alpronax","Intensol","Tricalma"],"Biological Half-Life":"Alprazolam has a mean plasma elimination half-life of 11.2 hours in healthy patients (range 6.3-26.9 hours). The mean half-life is 16.3 hours (range 9.0-26.9 hours) in the elderly, 21.8 hours (range 9.9-40.4 hours) in obese patients, and 19.7 hours (range 5.8-65.3 hours) in patients with alcoholic liver disease. The half-life is 25% higher in Asian patients compared to Caucasians. Other studies have shown the half-life to be 9-16h. The extended-release formulation has a half-life of 10.7-15.8 hours in healthy adult patients.","CAS":"28981-97-7","ChEBI":"CHEBI:2611","ChEMBL":"CHEMBL661","ChemicalClasses":["triazolobenzodiazepine"],"Chirality":"achiral","Classes":null,"Color/Form":"Crystals from ethyl acetate","DEA no":2882,"Decomposition":"When heated to decomposition it emits toxic fumes of /hydrogen chloride/ and /nitric oxides/.","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","Drug Indication":"Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults. Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.  Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.","Drug Warnings":"Episodes of mania and hypomania have been reported in depressed patients receiving alprazolam.","DrugClasses":["opioid","depressant"],"DurationOfAction":"Instant-release:6 hoursExtended-release:11.3 hours","EINECS":"249-349-2","EliminationHalfLife":"Instant-release: 11~13 hoursExtended-release: 11~16 hours","Erowid Experience Reports":[{"Author":"Allegory","Id":"100577","Title":"Lost Time Ruined Marriage"},{"Author":"BluPill","Id":"107286","Title":"First Time, Blackout"},{"Author":"Igor","Id":"110146","Title":"Affluent College Addiction"},{"Author":"bmanh","Id":"110574","Title":"The Unrelenting Monster"},{"Author":"Pharmz","Id":"112620","Title":"20 Years of Daily Use"},{"Author":"Taylor","Id":"113260","Title":"End of My Xanax Days"},{"Author":"smalltown medic","Id":"113649","Title":"Double Edged Sword"},{"Author":"Johnny","Id":"114979","Title":"First Blackout Ever"},{"Author":"turboguaso","Id":"115751","Title":"No Recreation for Me"},{"Author":"xanaxsuccexx","Id":"116329","Title":"Using Less Than a Milligram at an Irregular Schedule"},{"Author":"Ian","Id":"18748","Title":"Memory Gone"},{"Author":"xan man","Id":"21123","Title":"I Was Black-Out for 4 Months"},{"Author":"Duke Raoul","Id":"29288","Title":"Good Times"},{"Author":"MaTT024","Id":"27620","Title":"Lost My Car After I Crashed It"},{"Author":"User","Id":"31764","Title":"OD'ed and Didnt Know It"},{"Author":"David","Id":"32794","Title":"Just Kinda Chill"},{"Author":"GrantB","Id":"35926","Title":"I Did Not Even Know What Day It Was"},{"Author":"Dex is 1337","Id":"36068","Title":"Sleepwalking? Maybe So, Maybe Not"},{"Author":"JuDndf","Id":"40756","Title":"Everything Was Blurred and Kind of Confusing"},{"Author":"Johnny Mota","Id":"40799","Title":"Is This the Bathroom, or My Bed?"},{"Author":"Leigh","Id":"48097","Title":"Not My Friend"},{"Author":"Gripped","Id":"48450","Title":"Life in the Whirl"},{"Author":"Little Weery","Id":"49067","Title":"Quite a Time"},{"Author":"Andrew","Id":"49960","Title":"I Don't Remember"},{"Author":"Jeff","Id":"50203","Title":"This Sucked"},{"Author":"thujone","Id":"51899","Title":"Zombie for a Week"}],"European Community (EC) Number":"432-090-6","FDA Pharmacological Classification":"YU55MQ3IZY","FullSalts":["Alprazolam dihydrate"],"HMDB ID":"HMDB0014548","HeavyAtomCount":22,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","IUPACName":"8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine","Impurities":["oxazepam benzophenone","2-(2-acetylhydrazino)-7-chloro-5-phenyl-3h-1,4-benzodiazepine","(5-chloro-2-(3-(chloromethyl)-5-methyl-4h-1,2,4-triazol-4-yl)phenyl)(phenyl)methanone","7-chloro-1-methyl-5-phenyl(1,2,4)triazolo(4,3-a)quinolin-4-amine","bis((4-(2-benzoyl-4-chlorophenyl)-5-methyl-4h-1,2,4-triazol-3-yl)methyl)amine","8-chloro-1-ethenyl-6-phenyl-4h-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine","2,17-dichloro-6,13-dimethyl-18b,19a-diphenyl-8b,19adihydro-10h,18bh-(1,2,4)triazolo(4''',3''':1'',2'')quinolo(3'',4'':4',5')oxazolo(3',2'-d)-1,2,4-triazolo(4,3-a)(1,4)benzodiazepine","3-amino-6-chloro-2-methyl-4-phenyl-3,4-dihydroquinazolin-4-ol","(5-chloro-2-(3-(hydroxymethyl)-5-methyl-4h-1,2,4-triazol-4-yl)phenyl)phenylmethanone","(5-chloro-2-(3-methyl-4h-1,2,4-triazol-4-yl)phenyl)phenylmethanone","(5-chloro-2-(3-(((6rs)-8-chloro-6-hydroxy-1-methyl-6-phenyl-4h-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepin-5(6h)-yl)methyl)-5-methyl-4h-1,2,4-triazol-4-yl)phenyl)phenylmethanone"],"InChI":"InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3","InChIKey":"VREFGVBLTWBCJP-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)","Melting Point":"228-229.5 °C","MolecularFormula":"C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e13\u003c/sub\u003eClN\u003csub\u003e4\u003c/sub\u003e","MolecularWeight":"308.8 g/mol","Pharmacodynamics":"Alprazolam is a benzodiazepine that binds γ-aminobutyric acid (GABA) type-A receptors (GABA\u003csub\u003eA\u003c/sub\u003eRs) to enhance their inhibitory effect on neurotransmission, specifically in the brain. Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death; patients taking benzodiazepines and opioids concurrently may require lower doses of one or both medications, depending on their clinical situation. Patients with pre-existing impaired respiratory function are at increased risk of adverse effects including death during treatment with benzodiazepines. In addition, due to its CNS depressant effects, patients taking alprazolam should avoid operating heavy machinery or driving and should avoid other CNS depressants such as alcohol. As with other benzodiazepines, alprazolam carries a risk of abuse, misuse, and addiction, which is higher in predisposed individuals and may require strict monitoring. Cessation of therapy may result in acute or protracted withdrawal symptoms, which may be life-threatening; the patient dose should be gradually tapered whenever discontinuation or reduced dosage are necessary. Newborns born to mothers using alprazolam later in pregnancy may suffer from sedation and withdrawal symptoms. As CYP3A is required for the initial step in alprazolam metabolism, alprazolam is contraindicated in patients taking strong CYP3A inhibitors, such as ketoconazole and itraconazole; milder CYP3A inhibitors still necessitate alprazolam dosage adjustments. Lastly, benzodiazepines may have negative effects, such as panic disorders, increased suicide incidence, and episodes of mania/hypomania, in patients suffering from depression.","Physical Description":"Solid","PrevSalts":["dihydrate"],"PubChemId":2118,"Record Description":["Alprazolam can cause developmental toxicity according to state or federal government labeling requirements.","Alprazolam is a member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug. It has a role as an anxiolytic drug, an anticonvulsant, a muscle relaxant, a sedative, a GABA agonist and a xenobiotic. It is a triazolobenzodiazepine and an organochlorine compound.","Alprazolam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981.","Alprazolam is a Benzodiazepine.","Alprazolam is an orally available benzodiazepine used predominantly for therapy of anxiety. As with most benzodiazepines, alprazolam t has not been associated with serum aminotransferase or alkaline phosphatase elevations during therapy, and clinically apparent liver injury from alprazolam has been reported but is very rare.","Alprazolam is a triazolobenzodiazepine agent with anxiolytic, sedative-hypnotic and anticonvulsant activities. Alprazolam binds to a specific site distinct from the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) binding site on the benzodiazepine-GABA-A-chloride ionophore receptor complex located in the limbic, thalamic and hypothalamic regions of the central nervous system (CNS). This binding causes an allosteric modification of the receptor and enhances the affinity of GABA to the receptor leading to an increase in the frequency of chloride-channel opening events. This leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential and leads to a decrease in neuronal excitability.","ALPRAZOLAM is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA.","Alprazolam is only found in individuals that have used or taken this drug. It is a triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of panic disorders, with or without agoraphobia, and in generalized anxiety disorders. (From AMA Drug Evaluations Annual, 1994, p238) Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA\u003csub\u003eA\u003c/sub\u003e) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.","A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)","Alprazolam can cause developmental toxicity according to state or federal government labeling requirements.","Alprazolam is a member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug. It has a role as an anxiolytic drug, an anticonvulsant, a muscle relaxant, a sedative, a GABA agonist and a xenobiotic. It is a triazolobenzodiazepine and an organochlorine compound.","LiverTox|CNS|Sedative/Hypnotic|Benzodiazepine"],"RefCount":4,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Alprazolam","Name":"Alprazolam","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q319877","Name":"Alprazolam","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00404","Name":"Alprazolam","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/2118","Name":"Alprazolam","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL661","Name":"Alprazolam","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2611","Name":"Alprazolam","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=28981-97-7","Name":"Alprazolam","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014548","Name":"Alprazolam","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D00225","Name":"Alprazolam","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/YU55MQ3IZY","Name":"Alprazolam","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID4022577","Name":"Alprazolam","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 2118, Alprazolam. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/2118\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/2118\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Alprazolam. UNII: YU55MQ3IZY. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/YU55MQ3IZY\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/YU55MQ3IZY\u003c/a\u003e","Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024. May 30, 2024. Accessed June 26, 2025. \u003ca href=https://www.legislation.gov.au/F2024L00589/latest/text\u003ehttps://www.legislation.gov.au/F2024L00589/latest/text\u003c/a\u003e"],"SMILES":"CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4","Salts":["dihydrate"],"SaltsAcidCount":[0],"SaltsAmineCount":[1],"SaltsUNII":["2I8KVA57TM"],"Scheduling":[{"gov":"Australia","ref":["3"],"schedule":"S8 substance"},{"gov":"Brazil","ref":[],"schedule":"B1 substance"},{"gov":"Canada","ref":[],"schedule":"Schedule IV substance"},{"gov":"Germany","ref":[],"schedule":"Anlage III substance"},{"gov":"United Kingdom","ref":[],"schedule":"prescription only substance"},{"act":"Controlled Substances Act (CSA)","gov":"United States","ref":[],"schedule":"Schedule I"},{"gov":"European Union","ref":[],"schedule":"prescription only substance"},{"act":"Convention on Psychotropic Substances 1971","gov":"United Nations","ref":[],"schedule":"Schedule IV drug"}],"Solubility":"Insoluble in water","Stability/Shelf Life":"Stable under recommended storage conditions.","StoreUNII":["YU55MQ3IZY"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="104.096mm" version="1.2" viewBox="0 0 82.075 104.096" width="82.075mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="105.0" stroke="none" width="83.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="42.507" x2="55.557" y1="1.068" y2="8.939"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="66.367" x2="55.557" y1="4.374" y2="8.939"/>
                        
                <line x1="67.316" x2="58.138" y1="6.62" y2="10.496"/>
                      
                <line class="hi" stroke="#3050F8" x1="66.367" x2="60.962" y1="4.374" y2="6.656499999999999"/>
                <line class="hi" stroke="#3050F8" x1="67.316" x2="62.727000000000004" y1="6.62" y2="8.558"/>
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="72.455" x2="76.717" y1="6.31" y2="11.232"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="71.695" x2="77.371" y1="27.578" y2="18.181"/>
                        
                <line x1="70.524" x2="75.284" y1="24.801" y2="16.92"/>
                      
                <line class="hi" stroke="#3050F8" x1="77.371" x2="74.53299999999999" y1="18.181" y2="22.8795"/>
                <line class="hi" stroke="#3050F8" x1="75.284" x2="72.904" y1="16.92" y2="20.860500000000002"/>
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="71.695" x2="60.166" y1="27.578" y2="24.893"/>
                  
            <line class="bond" id="mol1bnd6" x1="55.557" x2="56.531" y1="8.939" y2="20.279"/>
                  
            <line class="bond" id="mol1bnd7" x1="53.83" x2="44.975" y1="26.559" y2="33.674"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="44.975" x2="44.975" y1="48.914" y2="33.674"/>
                        
                <line x1="42.536" x2="42.536" y1="47.505" y2="35.082"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="44.975" x2="31.767" y1="48.914" y2="56.534"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="18.559" x2="31.767" y1="48.914" y2="56.534"/>
                        
                <line x1="20.997" x2="31.767" y1="47.505" y2="53.719"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="18.559" x2="18.559" y1="48.914" y2="33.674"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="31.767" x2="18.559" y1="26.054" y2="33.674"/>
                        
                <line x1="31.767" x2="20.997" y1="28.869" y2="35.082"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="44.975" x2="31.767" y1="33.674" y2="26.054"/>
                  
            <line class="bond" id="mol1bnd14" x1="18.559" x2="6.875" y1="48.914" y2="55.662"/>
                  
            <line class="bond" id="mol1bnd15" x1="44.975" x2="56.862" y1="48.914" y2="58.464"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="56.862" x2="68.391" y1="58.464" y2="55.779"/>
                        
                <line x1="57.464" x2="67.838" y1="55.82" y2="53.404"/>
                      
                <line class="hi" stroke="#3050F8" x1="68.391" x2="62.62650000000001" y1="55.779" y2="57.1215"/>
                <line class="hi" stroke="#3050F8" x1="67.838" x2="62.650999999999996" y1="53.404" y2="54.612"/>
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="73.482" x2="78.299" y1="51.298" y2="41.294"/>
                  
            <line class="bond" id="mol1bnd18" x1="71.695" x2="78.299" y1="27.578" y2="41.294"/>
                  
            <line class="bond" id="mol1bnd19" x1="56.862" x2="53.476" y1="58.464" y2="73.323"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="64.662" x2="53.476" y1="83.687" y2="73.323"/>
                        
                <line x1="61.971" x2="52.851" y1="84.518" y2="76.068"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="64.662" x2="61.276" y1="83.687" y2="98.546"/>
                  
            <g class="bond" id="mol1bnd22">
                        
                <line x1="46.705" x2="61.276" y1="103.042" y2="98.546"/>
                        
                <line x1="47.331" x2="59.211" y1="100.297" y2="96.631"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd23" x1="46.705" x2="35.52" y1="103.042" y2="92.678"/>
                  
            <g class="bond" id="mol1bnd24">
                        
                <line x1="38.906" x2="35.52" y1="77.819" y2="92.678"/>
                        
                <line x1="40.97" x2="38.21" y1="79.734" y2="91.847"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd25" x1="53.476" x2="38.906" y1="73.323" y2="77.819"/>
                  
            <path class="atom" d="M71.538 5.459h-.72l-2.619 -4.066h-.03q.012 .239 .03 .596q.023 .357 .023 .732v2.738h-.565v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm3" stroke="none"/>
                  
            <path class="atom" d="M81.515 16.982h-.72l-2.62 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm4" stroke="none"/>
                  
            <path class="atom" d="M58.802 26.573h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M2.906 54.72q-.786 .0 -1.239 .53q-.452 .524 -.452 1.447q-.0 .91 .417 1.446q.422 .53 1.268 .53q.321 -.0 .607 -.054q.292 -.059 .565 -.142v.535q-.273 .102 -.565 .149q-.292 .054 -.697 .054q-.744 -.0 -1.25 -.31q-.5 -.309 -.75 -.875q-.25 -.571 -.25 -1.339q.0 -.745 .268 -1.31q.274 -.566 .804 -.881q.529 -.322 1.279 -.322q.78 .0 1.352 .286l-.244 .524q-.226 -.101 -.506 -.185q-.274 -.083 -.607 -.083zM5.662 59.143h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm13" stroke="none"/>
                  
            <path class="atom" d="M73.636 57.459h-.72l-2.62 -4.066h-.029q.012 .239 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.023 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm15" stroke="none"/>
                
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="72.455" x2="74.586" y1="6.31" y2="8.770999999999999"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="76.717" x2="74.586" y1="11.232" y2="8.770999999999999"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="60.166" x2="65.9305" y1="24.893" y2="26.235500000000002"/>
            <line class="hi" id="mol1bnd6" stroke="#3050F8" x1="56.531" x2="56.044" y1="20.279" y2="14.609"/>
            <line class="hi" id="mol1bnd7" stroke="#3050F8" x1="53.83" x2="49.4025" y1="26.559" y2="30.116500000000002"/>
            <line class="hi" id="mol1bnd14" stroke="#1FF01F" x1="6.875" x2="12.717" y1="55.662" y2="52.288"/>
            <line class="hi" id="mol1bnd17" stroke="#3050F8" x1="73.482" x2="75.8905" y1="51.298" y2="46.296"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Therapeutic Uses":"Anti-Anxiety Agents; GABA Modulators; Hypnotics and Sedatives","Title":"Alprazolam","UNII":"YU55MQ3IZY","Wikidata":"Q319877","Wikipedia":"Alprazolam","XLogP":2.1}